- Home
- MRAM vs KPTI Comparison
MRAM vs KPTI Comparison
Compare MRAM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- KPTI
- Stock Information
- Founded
- MRAM 2008
- KPTI 2008
- Country
- MRAM United States
- KPTI United States
- Employees
- MRAM N/A
- KPTI N/A
- Industry
- MRAM Semiconductors
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- KPTI Health Care
- Exchange
- MRAM Nasdaq
- KPTI Nasdaq
- Market Cap
- MRAM 121.1M
- KPTI 121.2M
- IPO Year
- MRAM 2016
- KPTI 2013
- Fundamental
- Price
- MRAM $5.81
- KPTI $0.89
- Analyst Decision
- MRAM Strong Buy
- KPTI Strong Buy
- Analyst Count
- MRAM 2
- KPTI 4
- Target Price
- MRAM $9.00
- KPTI $5.00
- AVG Volume (30 Days)
- MRAM 101.2K
- KPTI 864.9K
- Earning Date
- MRAM 10-30-2024
- KPTI 10-31-2024
- Dividend Yield
- MRAM N/A
- KPTI N/A
- EPS Growth
- MRAM N/A
- KPTI N/A
- EPS
- MRAM 0.07
- KPTI N/A
- Revenue
- MRAM $58,238,000.00
- KPTI $145,668,000.00
- Revenue This Year
- MRAM N/A
- KPTI $6.41
- Revenue Next Year
- MRAM $8.94
- KPTI $11.85
- P/E Ratio
- MRAM $79.46
- KPTI N/A
- Revenue Growth
- MRAM N/A
- KPTI N/A
- 52 Week Low
- MRAM $4.89
- KPTI $0.62
- 52 Week High
- MRAM $10.50
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- MRAM 53.49
- KPTI 62.92
- Support Level
- MRAM $5.54
- KPTI $0.71
- Resistance Level
- MRAM $6.08
- KPTI $0.94
- Average True Range (ATR)
- MRAM 0.24
- KPTI 0.07
- MACD
- MRAM 0.02
- KPTI 0.02
- Stochastic Oscillator
- MRAM 68.40
- KPTI 78.86
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.